Pharmaceutical giant AstraZeneca announced Thursday that its three-drug cancer treatment has demonstrated remarkable success in delaying disease advancement among liver cancer patients during a major clinical study.
The company reported that patients receiving a combination of Imfinzi, Imjudo, and lenvatinib alongside standard liver cancer procedures experienced significantly longer periods without their cancer progressing compared to those who received only conventional treatment.
The study focused on patients with hepatocellular carcinoma (HCC), the most prevalent form of liver cancer that cannot be surgically removed. Researchers compared the new drug combination against transarterial chemoembolisation (TACE), a standard procedure where doctors inject chemotherapy directly into liver tumors and then cut off their blood supply.
According to the trial results, the experimental treatment achieved what researchers called “statistically significant and clinically meaningful improvement” in preventing disease progression. Early analysis also suggested patients lived longer overall when receiving the combination therapy.
The treatment protocol involved giving patients an initial dose of Imjudo, followed by regular Imfinzi injections and lenvatinib pills, administered before and during the TACE procedure.
Susan Galbraith, a senior executive at AstraZeneca, stated the findings demonstrate that beginning this treatment regimen earlier, combined with TACE and lenvatinib, could lead to even better patient outcomes.
Financial analysts are optimistic about the combination’s commercial potential. JP Morgan and Citi analysts both project the Imfinzi-Imjudo pairing could generate peak annual revenues of approximately $11.3 billion, exceeding current market predictions of $10.6 billion.
This positive news follows AstraZeneca’s announcement last week about another experimental drug showing promise for chronic lung disease patients, which boosted the company’s stock price by nearly 4 percent.
